According to the new market research report “Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) – Global Forecast to 2021“, published by MarketsandMarkets™,The global immunotherapy drugs market is projected to reach USD 201.52 Billion by 2021 from USD 108.41 Billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021.
Don’t miss out on business opportunities in Immunotherapy Drugs Market
Increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. On the other hand, the high cost of immunotherapy treatment, and high attrition rate in the product development cycle are the major factors hindering the growth of the market. However, rising opportunities in the emerging markets, and immunotherapy as an alternative to chemotherapy for first line treatment are the factors supporting the growth of the market.
Target Audience
- Pharmaceuticals Manufacturers
- Research & Academic Institutions
- Hospitals and clinics
- Contract Manufacturers
- Contract Research Organizations
To know about the assumptions considered for the study, download the pdf brochure
Browse and in-depth TOC on “Immunotherapy drugs Market”
79 – Tables
44 – Figures
174 – Pages
Get Free 10% customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=137717755
Company Information
Detailed analysis and profiling of additional market players
The global immunotherapy drugs market is projected to reach USD 201.52 Billion by 2021 from USD 108.41 Billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021.
Increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. On the other hand, the high cost of immunotherapy treatment, and high attrition rate in the product development cycle are the major factors hindering the growth of the market. However, rising opportunities in the emerging markets, and immunotherapy as an alternative to chemotherapy for first line treatment are the factors supporting the growth of the market.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
